Monday - October 26, 2026
MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma
October 07, 2026
BUFFALO, New York, Oct. 7 [Category: BizHospital] -- The Roswell Park Comprehensive Cancer Center posted the following news release:

* * *

MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma

*

Statistical significance in overall survival benefit was achieved in patients aged 65 and under

* Long-term survival in those 65 and under

* Findings consistent with re . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products